These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1174 related articles for article (PubMed ID: 25686114)

  • 21. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
    Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
    Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective.
    Fleeman N; Bagust A; Beale S; Boland A; Dickson R; Dwan K; Richardson M; Dundar Y; Davis H; Banks L
    Pharmacoeconomics; 2015 Sep; 33(9):893-904. PubMed ID: 25906420
    [TBL] [Abstract][Full Text] [Related]  

  • 23. PD-L1 status does not predict the outcome of BRAF inhibitor therapy in metastatic melanoma.
    Schaper-Gerhardt K; Okoye S; Herbst R; Ulrich J; Terheyden P; Pföhler C; Utikal JS; Kreuter A; Mohr P; Dippel E; Satzger I; Sucker A; Schadendorf D; Ugurel S; Gutzmer R
    Eur J Cancer; 2018 Jan; 88():67-76. PubMed ID: 29195116
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vemurafenib: in unresectable or metastatic melanoma.
    Keating GM
    BioDrugs; 2012 Oct; 26(5):325-34. PubMed ID: 22946753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The discovery of vemurafenib for the treatment of BRAF-mutated metastatic melanoma.
    Kim A; Cohen MS
    Expert Opin Drug Discov; 2016 Sep; 11(9):907-16. PubMed ID: 27327499
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Management of Treatment-Related Adverse Events with Agents Targeting the MAPK Pathway in Patients with Metastatic Melanoma.
    Daud A; Tsai K
    Oncologist; 2017 Jul; 22(7):823-833. PubMed ID: 28526719
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Vemurafenib in patients with BRAF V600E mutation-positive advanced melanoma.
    Ravnan MC; Matalka MS
    Clin Ther; 2012 Jul; 34(7):1474-86. PubMed ID: 22742884
    [TBL] [Abstract][Full Text] [Related]  

  • 28. BRAF and MEK inhibition for the treatment of advanced BRAF mutant melanoma.
    Richman J; Martin-Liberal J; Diem S; Larkin J
    Expert Opin Pharmacother; 2015 Jun; 16(9):1285-97. PubMed ID: 26001180
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Vemurafenib: an evidence-based review of its clinical utility in the treatment of metastatic melanoma.
    Swaika A; Crozier JA; Joseph RW
    Drug Des Devel Ther; 2014; 8():775-87. PubMed ID: 24966667
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BRIM-1, -2 and -3 trials: improved survival with vemurafenib in metastatic melanoma patients with a BRAF(V600E) mutation.
    Young K; Minchom A; Larkin J
    Future Oncol; 2012 May; 8(5):499-507. PubMed ID: 22646765
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
    Dhillon S
    Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
    [TBL] [Abstract][Full Text] [Related]  

  • 32. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
    Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
    Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma.
    Hu-Lieskovan S; Mok S; Homet Moreno B; Tsoi J; Robert L; Goedert L; Pinheiro EM; Koya RC; Graeber TG; Comin-Anduix B; Ribas A
    Sci Transl Med; 2015 Mar; 7(279):279ra41. PubMed ID: 25787767
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Which drug, and when, for patients with BRAF-mutant melanoma?
    Jang S; Atkins MB
    Lancet Oncol; 2013 Feb; 14(2):e60-9. PubMed ID: 23369684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
    Queirolo P; Picasso V; Spagnolo F
    Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Preexisting MEK1P124 mutations diminish response to BRAF inhibitors in metastatic melanoma patients.
    Carlino MS; Fung C; Shahheydari H; Todd JR; Boyd SC; Irvine M; Nagrial AM; Scolyer RA; Kefford RF; Long GV; Rizos H
    Clin Cancer Res; 2015 Jan; 21(1):98-105. PubMed ID: 25370473
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Vemurafenib. Value unclear in metastatic melanoma.
    Prescrire Int; 2012 Dec; 21(133):288-90. PubMed ID: 23373092
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma.
    Spagnolo F; Ghiorzo P; Queirolo P
    Oncotarget; 2014 Nov; 5(21):10206-21. PubMed ID: 25344914
    [TBL] [Abstract][Full Text] [Related]  

  • 39. FDA approval summary: vemurafenib for treatment of unresectable or metastatic melanoma with the BRAFV600E mutation.
    Kim G; McKee AE; Ning YM; Hazarika M; Theoret M; Johnson JR; Xu QC; Tang S; Sridhara R; Jiang X; He K; Roscoe D; McGuinn WD; Helms WS; Russell AM; Miksinski SP; Zirkelbach JF; Earp J; Liu Q; Ibrahim A; Justice R; Pazdur R
    Clin Cancer Res; 2014 Oct; 20(19):4994-5000. PubMed ID: 25096067
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma.
    Van Allen EM; Wagle N; Sucker A; Treacy DJ; Johannessen CM; Goetz EM; Place CS; Taylor-Weiner A; Whittaker S; Kryukov GV; Hodis E; Rosenberg M; McKenna A; Cibulskis K; Farlow D; Zimmer L; Hillen U; Gutzmer R; Goldinger SM; Ugurel S; Gogas HJ; Egberts F; Berking C; Trefzer U; Loquai C; Weide B; Hassel JC; Gabriel SB; Carter SL; Getz G; Garraway LA; Schadendorf D;
    Cancer Discov; 2014 Jan; 4(1):94-109. PubMed ID: 24265153
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 59.